Entera Bio Ltd. (ENTX)
Last updated: 2026-10-20 21:18:20. Prices reflect the latest after-hours trading data. Stock price data is sourced from Massive.
Summary
Entera Bio Ltd. (ENTX) operates in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) sector and is listed on NASDAQ. The stock is currently priced at $3.02, with a market capitalization of $465.88M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $0.91 to $4.20. This page covers its latest market performance, valuation, price trends and company information.
Key Market Data
$465.88M | |
$2.79 | |
$10.16 | |
$0.30 | |
$2.94 | |
783.31K | |
1.93M | |
-- | |
$4.20 | |
$0.91 | |
-- | |
-- |
Entera Bio Ltd. (ENTX) After-Hours Stock Price
Entera Bio Ltd. (ENTX) is trading at $2.92 in after-hours trading as of 2026-10-20 20:45:00, down 0.65% ($0.02) from the regular-session close of $2.94.
After-hours trading shows how investors are pricing ENTX after the regular session closes. The current after-hours price is below the regular-session close, indicating cautious after-hours sentiment.
Entera Bio Ltd. (ENTX) 7-Day Stock Price Change
Over the past seven days, Entera Bio Ltd. (ENTX) moved from $2.66 to $3.02, representing a gain of 13.46% ($0.36).
The stock traded between $2.44 and $3.26 during the period. The latest price is near the upper end of the 7-day range, indicating strong upward.
The average daily volume was 914.79 thousand shares, up versus the previous seven-day period, indicating higher trading activity.
ENTX 52-Week Price Position
Position in Range: 64.1%
ENTX is currently trading at $3.02, placing it 64.1% of the way from its 52-week low of $0.91 to its 52-week high of $4.20. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
What is Entera Bio Ltd. (ENTX)?
Entera Bio Ltd is a clinical-stage biopharmaceutical company engaged in the development of orally delivered macromolecule therapeutics, including peptides and therapeutic proteins. The company focuses on underserved, chronic medical conditions where oral administration of a mini tablet peptide or peptide replacement therapy has the potential to perform. Its product candidates are: EB613, which is being developed as an oral, osteoanabolic (bone-building) tablet treatment for osteoporosis; EB612, being developed as an oral PTH(1-34) tablet peptide replacement therapy for patients with hypoparathyroidism; EB618, an Oral GLP-1 being developed to tackle obesity; and Oral GLP-2, a peptide tablet alternative for patients suffering from short bowel syndrome. The company operates in Israel.
Entera Bio Ltd. Information
| Industry | BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) |
| Employees | 22 |
| Exchange | NASDAQ |
| Company Website |
How to Buy Entera Bio Ltd. (ENTX) Stock on MEXC
Eligible investors can buy real shares of Entera Bio Ltd. (ENTX) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.
Frequently Asked Questions (FAQ)
1.What is Entera Bio Ltd. (ENTX) stock price today?
2.Is ENTX stock going up or down today?
3.What is ENTX pre-market price?
4.What is ENTX after-hours price?
5.Is ENTX stock trading now?
6.Where does ENTX sit relative to its 52-week high and low?
7.What sector is Entera Bio Ltd. in?
8.What is Entera Bio Ltd.'s market capitalization and where is it listed?
9.How is ENTX valued in terms of P/E ratio and EPS?
10.Does Entera Bio Ltd. pay a dividend?
Explore More US Stocks
Search Stocks
ENTX Stock Calculator
Estimate the value between ENTX shares and USD.
ENTX Shares to USD
1.00 ENTX shares = 3.018 USD
Calculations are estimates based on the latest available price and are for reference only.


